New Patent Further Expands MultiStat's International Intellectual Property Protection
GAINESVILLE, FL -- (MARKETWIRE) -- 08/14/12 -- Quick-Med Technologies, Inc. (OTCQB: QMDT) (PINKSHEETS: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the Canadian Intellectual Property Office has granted Canadian Patent No. 2,446,356 entitled "Use of Compositions for Treating Rosacea." MultiStat is a family of groundbreaking compounds designed to prevent and repair skin damage.
The new patent extends the current international intellectual property for the Company's MultiStat® family of compounds. It is part of a patent portfolio that Quick-Med has licensed from the University of Michigan and is similar to U.S. Patent No. 7,795,302. It remains in effect until May 9, 2022.
The patent covers methods that supplement traditional treatment of rosacea by addressing the inflammatory and collagen-degrading components of the skin condition. It covers patent claims that address methods for treating rosacea with an antimicrobial, a retinoid, and an inhibitor of toll-like receptors in both topical and oral applications. The broad range of antimicrobials to be utilized in combination with the MultiStat family includes tetracycline, erythromycin, azithromycin, clarithromycin, milbemycin, aminoglycoside, penicillin (optimally in combination with a beta-lactamase inhibitor), cephalosporin, fluoroquinolone, streptogramin and sulfanomide.
"Our MultiStat technology has shown significant improvement in the appearance of skin, by promoting the maintenance, healing and repair," said Bernd Liesenfeld, Quick-Med President. "We are pleased that this granted patent will allow us to license our MultiStat patent estate to help a broad population looking for products that provide relief from Rosacea skin conditions."
Rosacea is a chronic skin condition involving inflammation of the cheeks, nose, chin, forehead, or eyelids. It may appear as redness, prominent spider-like blood vessels, swelling, or skin eruptions similar to acne. According to the National Rosacea Society an estimated 16 million Americans currently suffer from rosacea.
MultiStat® is Quick-Med's family of patented matrix metalloproteinase inhibitors (MMPIs), which have been shown to be highly effective in reducing skin wrinkling and aging. The MultiStat family consists of 10 patented compounds, patented formulae for developing other compounds, numerous use or method patents and other intellectual property involving the use of MMP inhibition techniques in skin therapy. These MMPIs, which have been proven effective in broad-based applications, including improving the appearance of fine lines and wrinkles associated with natural aging or sun-induced premature aging and damage, are marketed to the cosmetics industry as performance ingredients in commercially available anti-aging creams. Quick-Med currently owns or has exclusive licenses for topical uses of MultiStat compounds for cosmetic and military applications.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. In addition to MultiStat, the Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. It's new Stay Fresh® technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.
© 2012 Quick-Med Technologies, Inc. All rights reserved. MultiStat®, NIMBUS®, and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
Bernd Liesenfeld, President
(888) 835.2211 Ext 103